Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

FDA accepts Striant NDA for review

Oct. 23, 2002

Small-molecule MC4 receptor agonist with effects on food intake and erectile activity

Oct. 21, 2002

Columbia and Ardana enter European marketing partnership for Striant

Oct. 18, 2002

Novel PDE5 inhibitors developed by Lilly Icos researchers

Oct. 18, 2002

cGMP-selective PDE inhibitors under study at Bayer

Oct. 18, 2002

Duloxetine in urinary stress incontinence

Oct. 17, 2002

Novel potassium channel openers under study at Abbott

Oct. 17, 2002

Novel agents for urinary incontinence covered by Boehringer Ingelheim patent

Oct. 15, 2002

Merck patent covers novel alpha1A-adrenoceptor antagonists and their use in BPH

Oct. 14, 2002

Dutasteride approved for launch as first dual-acting 5alpha-reductase inhibitor for BPH

Oct. 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...